Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Savient target lowered to $18 from $26 at Roth Capital
Roth Capital lowered its target on Savient as the firm had previously assumed that the company would launch Krystexxa with a large partner, but the odds of that now seem lower, according to the firm.However, Roth is still optimistic about the drug's outlook and the firm maintains a Buy rating on Savient.
APPA Volume spiked 10 folds, news may be coming regarding the APF530 CINV.
APPA Volume spiked 10 folds, news may be coming regarding the APF530 CINV.
From Oppenhiemer
Timing of Filing May Suggest A Weak Application. We note that Silenor was
not commercially available until late August and this filing was received by the FDA on 9/16, suggesting the generic filer both generated bioequivalence data and submitted data to the FDA in less than one month, when the process normally can take 6mos.
Our Model Assumes Silenor Receives Patent Protection Through 2018.
Although it is unclear which patents will be challenged, we note that Silenor is currently protected by two method of use patents (6,211,229 and 5,502,047),
the latest of which covers Silenor through 2020. Our current model assumes generic competition in 2018.
Momentum: Have you seen SOMX, todays low to $3.18
Momentum, COCO down to $5 is it worth to get in?
This is Huge GLTA Longs:10.2%
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7143214
IS FDA requested for any additional clinical trials?
What does it mean: although the Agency has asked for the re-presentation and re-analysis of select existing Phase 3 clinical trial data.
I copied the following fda rersponse letter from ap pharma website.
Clinical
•The FDA did not request additional clinical efficacy studies, although the Agency has asked for the re-presentation and re-analysis of select existing Phase 3 clinical trial data.
•The FDA requested the Company perform two studies relating to bioavailability and metabolism. A.P. Pharma believes these studies should be of short duration in normal volunteers.
•The FDA did not accept the Company's request to waive the requirement for a thorough QT study. A.P. Pharma believes this study should be of short duration in normal volunteers. The Company plans to discuss the design and timing of the study with the FDA.
Last 30 minutes Volume @ 80,000. heavy volume.
Unusual Trading Activity for COCO:
NEW YORK (Market Intellisearch) -- COCO options saw interesting call activity today. A total of 311 put and 1,213 call contracts were traded raising a low Put/Call volume alert. Today's traded Put/Call ratio is 0.26. There were 3.90 calls traded for each put contract.
Not yet if class 1 then i guess 3 months, for class 2 will be 6 months. (for resubmission's)
S&P REITERATES HOLD OPINION ON SHARES OF CORINTHIAN COLLEGES
S&P REITERATES HOLD OPINION ON SHARES OF CORINTHIAN COLLEGES
(Standard & Poor's)
We have further reduced our EPS forecasts, after last week's announcement that COCO will no longer admit students under the federal Ability to Benefit program, which offers post-secondary education to those lacking high-school diplomas or equivalent. But we favor COCO's plan to sharply reduce the risk profile of its students, after its former students were shown to have very high loan default levels. We cut our EPS estimates by $0.45 each, to $1.35 in FY 11 (Jun) and $1.05 in FY 12.
Critical Insider Trade Alerts for Somaxon, Corinthian Colleges, Toll Brothers, Verifone, Veeco, & Everest Re; Reported by Insiderslab.com
10:00a ET August 26, 2010 (PR NewsWire)
Insiderslab.com issues new research reports that highlight large insider trades found in Somaxon, Corinthian Colleges, Toll Brothers, Verifone, Veeco, & Everest Re. Read our research reports with Interactive Insider Trading Charts and Insider Trade Statistics below.
Insiders refer to company Top Executive Officers (CEOs, CFOs, COOs) and Directors who are involved in making critical corporate decisions.
Somaxon Pharmaceuticals, Inc.: Market Option Sale made by company C-Level Officers on Aug 10th, at trade price (US$3.99). Disclose date: Aug 13th. Read Full Report: http://www.insiderslab.com/PR/082610A/SOMX/Somaxon (NASDAQ: SOMX)
Corinthian Colleges Inc.: Open-market Purchase made by company Directors on Aug 24th, at trade price (US$4.36). Disclose date: Aug 24th. Read Full Report: http://www.insiderslab.com/PR/082610A/COCO/Corinthian-Colleges (NASDAQ: COCO)
Toll Brothers Inc.: Market Option Sale made by company C-Level Officers and Directors. Read Full Report: http://www.insiderslab.com/PR/082610A/TOL/Toll-Brothers (NYSE: TOL)
Verifone Systems, Inc.: Market Option Sale made by company C-Level Officers on Aug 17th, at trade price (US$22.50). Disclose date: Aug 18th. Read Full Report: http://www.insiderslab.com/PR/082610A/PAY/Verifone (NYSE: PAY)
Veeco Instruments Inc.: Market Option Sale made by company C-Level Officers. Read Full Report: http://www.insiderslab.com/PR/082610A/VECO/Veeco (NASDAQ: VECO)
Everest Re Group Ltd.: Open-market Purchase made by company 10% Owners on Aug 24th, at trade price (US$80.27). Disclose date: Aug 24th. Read Full Report: http://www.insiderslab.com/PR/082610A/RE/Everest-Re (NYSE: RE)
There are thousands of insider filings on the stock markets every day. Insiderslab.com strives to turn this massive raw data into usable information that investors can use to do better research for their investments. Today Insiderslab.com issues new research reports on large insider trades found in the above Blue Chips or Penny Stock companies.
Subscribe for FREE insider trading alert newsletters that track all the stocks on the OTCBB, NASDAQ, SP500, DOWJ, and NYSE. Click here: http://www.insiderslab.com .
Every day, Insiderslab.com research analysts spend hours to track and monitor insider trading activities in the U.S. markets and issue Insider Trading Research Reports every day. Watch the next report tomorrow for one of the following research highlights:
1. Down by Half Purchases made by C-Level officers, Directors, and 10%
shareholders
2. Large purchases/sales made by C-Level officers
3. Large insiders sales at 52-week highs
4. Large insider purchases at 52-week lows
5. Consensus purchase/sales by a group of insiders
How many months does it take after submitting a new response to FDA. will it be again 10 months or less?
The first one took exactly 10 months.
SOMX ... moving up.
SOMX.... Moving up.
SOMX... Moving up
SOMX Moving up....
SOMX moving up..
Appa common stock offering.
Momentum, Are you playing EPCT? it is down 38% - common stock offering
URRE up in PM, will be above 200 day ma.
URRE up in PM, won 21 yr old court battle.
URRE up in Premarket, 21 year old court battle.
court ruled in favor oof URRE.
URRE going high in PM , won ruled in favor of URRE.
In play alret by briefing.
URRE up in premarket, won 21 yr old court battle.
Uranium stock.
URRE up in Premarket, won 21 yr old court battle.
URRE in Play.........
URRE last trade @ .82
Momentum, are u in ADG?
JAZZ UPGRADE price target raised to $15 from $12
Analysts at Barclays Capital upgrade Jazz Pharmaceuticals Inc (NASDAQ: JAZZ) from "equal weight" to "overweight." The target price for JAZZ has been raised from $12 to $15.
http://www.benzinga.com/trading-ideas/long-ideas/10/06/331555/barclays-upgrades-jazz-to-overweight
JAZZ UPGRADE price target raised to $15 from $12
Analysts at Barclays Capital upgrade Jazz Pharmaceuticals Inc (NASDAQ: JAZZ) from "equal weight" to "overweight." The target price for JAZZ has been raised from $12 to $15.
http://www.benzinga.com/trading-ideas/long-ideas/10/06/331555/barclays-upgrades-jazz-to-overweight
Momentum, are you still in MSHL?
DDD -42% crashing in the AH in for a bounce play.....
SCOLR pharma DDD down 40% bounce play....
Javelin file lawsuit against HOSPIRA, whats next?
Momentum are you still in JAV?
GTXI AH down 40%
GTX Inc has more than $60M revenue last year and $38M cash in hand. This company has one FDA-approval drug in the market already:
http://www.gtxinc.com/Pipeline/Overview.aspx?Sid=1
60 mg Toremifene Citrate is effective and safe for the treatment of metastatic breast cancer.
Also, the company has three more drugs in the pipeline.
I won't be surprised if this stock go back to above $3.
GTXI AH down 40%
GTX Inc has more than $60M revenue last year and $38M cash in hand. This company has one FDA-approval drug in the market already:
http://www.gtxinc.com/Pipeline/Overview.aspx?Sid=1
60 mg Toremifene Citrate is effective and safe for the treatment of metastatic breast cancer.
Also, the company has three more drugs in the pipeline.
I won't be surprised if this stock go back to above $3.
A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100526005605&newsLang=en